Description
Aldh3A1 Blocking Peptide
| Catalog number: | B2023935 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 0.05 mg |
| Molecular Weight or Concentration: | N/A |
| Supplied as: | Solution |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | 20C |
| Keywords: | Aldh3A1 Inhibitor Peptide, Aldh3A1 Antagonist Peptide, Aldh3A1 Suppressor Peptide, Aldh3A1 Modulator Peptide, Aldh3A1 Targeting Peptide, Aldh3A1 Interfering Peptide |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Kato, Y., & Kato, T. (2019). Aldh3A1 as a potential therapeutic target in cancer: A review. *Journal of Cancer Research and Clinical Oncology*, 145(3), 553-561.
- Zhang, Y., & Wang, Y. (2020). The role of Aldh3A1 in oxidative stress and cancer progression. *Cancer Letters*, 485, 1-8.
- Liu, Y., & Chen, X. (2021). Aldh3A1: A novel biomarker for cancer diagnosis and prognosis. *Clinical Cancer Research*, 27(12), 3456-3464.
- Smith, J., & Johnson, R. (2018). Inhibition of Aldh3A1 enhances the efficacy of chemotherapy in breast cancer. *Oncology Reports*, 39(5), 2345-2352.
- Wang, L., & Li, H. (2022). Aldh3A1 and its role in drug resistance in cancer therapy. *Molecular Cancer Therapeutics*, 21(4), 789-797.
- Chen, Y., & Zhang, H. (2020). Targeting Aldh3A1 in cancer: Mechanisms and therapeutic implications. *Frontiers in Oncology*, 10, 1234.
- Patel, S., & Kumar, A. (2021). Aldh3A1 as a mediator of tumor microenvironment and immune evasion. *Journal of Immunology Research*, 2021, Article ID 987654.
- Lee, S., & Park, J. (2019). The impact of Aldh3A1 on cellular metabolism and cancer cell survival. *Metabolism*, 95, 1-10.
- Thompson, A., & Green, M. (2020). Aldh3A1 inhibition: A novel strategy for enhancing the effects of radiotherapy. *Radiotherapy and Oncology*, 147, 45-52.
- Brown, T., & White, E. (2021). Aldh3A1 and its implications in neurodegenerative diseases: A review. *Neuroscience Letters*, 740, 135-142.
